<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136185</url>
  </required_header>
  <id_info>
    <org_study_id>IMG-7289-CTP-102</org_study_id>
    <nct_id>NCT03136185</nct_id>
  </id_info>
  <brief_title>IMG-7289 in Patients With Myelofibrosis</brief_title>
  <official_title>A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imago BioSciences,Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imago BioSciences,Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in
      patients with myelofibrosis.

      This study investigates the following:

        -  The safety and tolerability of IMG-7289

        -  The pharmacokinetics of IMG-7289 (performed in Phase 1/2a only)

        -  The pharmacodynamic effect of IMG-7289
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With enrollment complete in Phase 1/2a, expansion into Phase 2b has occurred. New patients
      will be enrolled into Phase 2b study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events, and changes in physical examination, vital signs and laboratory parameters [safety and tolerability]</measure>
    <time_frame>Assessed from the time of first dose through 28 days after end of treatment.</time_frame>
    <description>as measured by the frequent monitoring of: adverse events, physical examination and vital signs and laboratory parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Concentration (performed in Phase 1/2a only)</measure>
    <time_frame>Up to 3 months.</time_frame>
    <description>as measured by Cmin sampling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spleen Volume</measure>
    <time_frame>Baseline to each visit where the variable is measured.</time_frame>
    <description>Reduction in spleen volume based on MRI (or CT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Post-polycythemia Vera Myelofibrosis (PPV-MF)</condition>
  <condition>Post-essential Thrombocythemia Myelofibrosis (PET-MF)</condition>
  <condition>Primary Myelofibrosis (PMF)</condition>
  <arm_group>
    <arm_group_label>IMG-7289</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single starting dose with individualized dose titrations throughout</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMG-7289</intervention_name>
    <description>Differentiation therapy</description>
    <arm_group_label>IMG-7289</arm_group_label>
    <other_name>LSD1 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years

          -  Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for
             myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRT

          -  High or intermediate-2 risk disease, as defined per protocol

        Exclusion Criteria:

          -  Receiving other treatments for the condition (with exceptions and time limits)

          -  Major surgery in last 4 weeks, minor surgery in the last 2 weeks

          -  History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of
             Screening

          -  History of splenectomy

          -  Current use of prohibited medications

          -  A concurrent second active and nonstable malignancy

          -  Known HIV infection or active Hepatitis B or Hepatitis C virus infection

          -  Other hematologic/biochemistry requirements, as per protocol

          -  Use of investigational agent within last 14 days

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen Pettit</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Peppe</last_name>
    <phone>+1-415-529-5055</phone>
    <email>jennifer.peppe@imagobio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Jones</last_name>
    <email>amber.jones@imagobio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Pettit, MD</last_name>
      <phone>734-647-8901</phone>
      <email>krpettit@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Goethert, MD</last_name>
      <phone>0201 723 84706</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro M Vannucchi</last_name>
      <phone>390557947688</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Harrison</last_name>
      <phone>020 7188 4259</phone>
      <email>HaematologyResearchTeam@gstt.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>March 7, 2020</last_update_submitted>
  <last_update_submitted_qc>March 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LSD1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

